TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8827136
Drug: Centrifuge subjects
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Centrifuge subjects at G-LOC endpoints
Study: 1571611
Drug: Methylprednisolone (MP)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone (MP) administered within 8 hours of injury
Study: 3907988
Drug: sulindac (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulindac (200 mg twice daily)
Study: 31246603
Drug: Prophylactic haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic haloperidol (1 or 2 mg)
Study: 30251914
Drug: Intense Pulsed
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense Pulsed Light (IPL) treatment (14-16J/cm2) combined with Meibomian Gland Expression (MGX)
Study: 30251914
Drug: Sham IPL
Normalized name: IPL-344
DrugBank: IPL-344 (DB16958)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham IPL treatment (0J/cm2)
Study: 27344439
Drug: Dalteparin (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin (subcutaneous 200 IU/kg once daily during month 1, followed by 150 IU/kg once daily for months 2-6)
Study: 27344439
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonist (VKA) (once daily for 6 months, with initial overlapping subcutaneous dalteparin 200 IU/kg once daily for ≥5 days until INR was 2.0-3.0 for 2 consecutive days)
Study: 22551881
Drug: Calcium-vitamin D3
Normalized name: Calcium/Cholecalciferol 600 MG-5 MCG Oral Capsule, Liquid Filled [CALCIUM-VITAMIN D3]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-vitamin D3 fixed combination
Study: 22551881
Drug: Calcium plus
Normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium plus vitamin D3 separate combination
Study: 20861210
Drug: Polyphenols (PP)
Normalized name: Pomegranate Fruit Polyphenol Extract
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyphenols (PP) 50 mg
Study: 20861210
Drug: Polyphenols (PP)
Normalized name: Pomegranate Fruit Polyphenol Extract
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyphenols (PP) 200 mg
Study: 12819407
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy (group 1, G1)
Study: 12819407
Drug: No chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No chemotherapy (group 2, G2)
Study: 10625567
Drug: EMLA (topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMLA (topical analgesia cream)
Study: 31532004
Drug: Conventional hourly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional hourly rate method (CM)
Study: 26516810
Drug: Anticholinergic (AC)
Normalized name: Anticholinergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticholinergic (AC) treatment
Study: 3666688
Drug: Placebo (P)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (P) treatment
Study: 27371428
Drug: ICG-PDT (Indocyanine
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICG-PDT (Indocyanine green photodynamic therapy) with 0.1% ICG lotion applied for 30 minutes and long pulse diode laser, 3 treatments over 2 weeks
Study: 27371428
Drug: ICG-PDT (Indocyanine
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICG-PDT (Indocyanine green photodynamic therapy) with 0.1% ICG lotion applied for 30 minutes and long pulse diode laser, 5 treatments over 2 weeks
Study: 18849616
Drug: Cluster SIT
Normalized name: cluster fig extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cluster SIT (14 injections of house dust mite allergen within 6 weeks)
Study: 18849616
Drug: Classic SIT
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classic SIT (14 injections of house dust mite allergen within 14 weeks)
Study: 17093147
Drug: 11trans-18:1 and
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11trans-18:1 and 12trans-18:1 supplementation (3.0 g each per day for 6 weeks)
Study: 11692118
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of epinephrine into the thigh
Study: 11692118
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of epinephrine into the upper arm
Study: 11692118
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of epinephrine into the upper arm
Study: 31553500
Drug: Daily stressors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily stressors
Study: 23064476
Drug: 5-mg of
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-mg of alendronate and 0.5-µg of calcitriol (Maxmarvil®)
Study: 19920054
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric carboxymaltose (200 mg intravenous iron)
Study: 16491287
Drug: Calcium- and
Normalized name: Calcium- and magnesium-containing product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium- and vitamin D3-fortified milk (400 ml/day providing 1000 mg calcium and 800 IU vitamin D3)
Study: 12760893
Drug: Telithromycin (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telithromycin (800 mg once daily)
Study: 12760893
Drug: Amoxicillin‐clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin‐clavulanic acid (1 g of amoxicillin and 125 mg of clavulanic acid 3 times daily)
Study: 10690692
Drug: New low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: New low-dose warfarin induction regimen
Study: 8489296
Drug: Idarubicin 10
Normalized name: IDArubicin 10 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarubicin 10 mg/m2
Study: 8489296
Drug: Idarubicin 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarubicin 12 mg/m2
Study: 8489296
Drug: Idarubicin 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarubicin 15 mg/m2
Study: 8489296
Drug: Idarubicin in
Normalized name: idarubicin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarubicin in patients with prior anthracycline therapy
Study: 3813060
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg of intramuscular morphine 30‐60 min before induction
Study: 29948896
Drug: fasting associated
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fasting associated with intravenous heparin
Study: 25093868
Drug: Hochuekkito (oral)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hochuekkito (oral) for 24 weeks
Study: 22382523
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment group (CMG) treated with Chinese herbs for supplementing qi, nourishing yin and activating blood circulation, besides Western medicine treatment.
Study: 22382523
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment group (CMG)
Study: 22382523
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine group (WMG)
Study: 20669671
Drug: Chinese Medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese Medicine internal-external combined therapy (ipratropium bromide aerosol, ambroxol hydrochloride, Chinese recipe, acupoint sticking with Xiaochuan Plaster)
Study: 20669671
Drug: Atrovent Metered
Normalized name: ipratropium Metered Dose Inhaler [Atrovent]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrovent Metered Dose Inhalation, oral Mucosolvan, Bailing Capsule, acupoint sticking with dummy plaster (Control)
Study: 15944842
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors (for two years)
Study: 15944842
Drug: Sequential use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential use of improved metabolic control and ACE inhibitor therapy
Study: 6294433
Drug: Naloxone (opiate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (opiate receptor blockade)
Study: 30382806
Drug: Walking+supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walking+supplement
Study: 26748734
Drug: Nemonoxacin 500
Normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemonoxacin 500 mg and 750 mg
Study: 17351155
Drug: Orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 120 mg tid for 10 days combined with a low-calorie diet
Study: 15068431
Drug: Sub-Tenon infiltration
Normalized name: tenonitrozole
DrugBank: Tenonitrozole (DB13659)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-Tenon infiltration with 3 mL of bupivacaine 0.50%
Study: 15068431
Drug: Classical analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classical analgesic drugs (control group)
Study: 7835813
Drug: Abdomino-pelvic radiation
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdomino-pelvic radiation therapy (APRT)
Study: 27276742
Drug: Moringa Oleifera
Normalized name: Moringa Oleifera
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moringa Oleifera (MO) leaf at 0 g
Study: 27276742
Drug: Moringa Oleifera
Normalized name: Moringa Oleifera
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moringa Oleifera (MO) leaf at 1 g
Study: 27276742
Drug: Moringa Oleifera
Normalized name: Moringa Oleifera
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moringa Oleifera (MO) leaf at 2 g
Study: 27276742
Drug: Moringa Oleifera
Normalized name: Moringa Oleifera
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moringa Oleifera (MO) leaf at 4 g
Study: 27276742
Drug: Moringa Oleifera
Normalized name: Moringa Oleifera
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moringa Oleifera (MO) leaf at 4 g vs baseline (0 g)
Study: 18536623
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A vaccine administered concomitantly with pneumococcal conjugate vaccine
Study: 18536623
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A vaccine administered separately
Study: 15813838
Drug: Antibiotic combination
Normalized name: combinations of different antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic combination therapy (amoxicillin, tetracycline, and metronidazole for 2 weeks)
Study: 15813838
Drug: No-antibiotics group
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-antibiotics group
Study: 6362702
Drug: Brotizolam 0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brotizolam 0.50 mg
Study: 29950801
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine green (ICG) 7.5 mg intravenous dose
Study: 24577124
Drug: Rivaroxaban 10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 10, 15, or 20 mg once daily
Study: 24577124
Drug: Dabigatran 110
Normalized name: dabigatran 110 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran 110 or 150 mg twice daily
Study: 20082712
Drug: 7.5% hypertonic
Normalized name: SODIUM CHLORIDE 7.5 g in 100 mL ORAL LIQUID [7.5% Hypertonic Saline]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5% hypertonic saline in combination with 6% dextran‐70 (HSD)
Study: 1985006
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of domperidone
Study: 17586832
Drug: Standard GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard GnRH agonist long-protocol ovarian stimulation with double embryo transfer (n = 194)
Study: 11107744
Drug: High-dose melphalan
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose melphalan with autologous stem cell support
Study: 8818844
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg tablets with food
Study: 8818844
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg suspension with food
Study: 8818844
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg sachet with food
Study: 8818844
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg sachet (absolute bioavailability)
Study: 1468240
Drug: etodolac SR
Normalized name: Etodolac
DrugBank: Etodolac (DB00749)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: etodolac SR 600 mg daily
Study: 1468240
Drug: etodolac SR
Normalized name: Etodolac
DrugBank: Etodolac (DB00749)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: etodolac SR 1200 mg daily
Study: 24277680
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec (0.4 U/kg, single subcutaneous dose)
Study: 19953628
Drug: Provox HiFlow
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Provox HiFlow HME (L‐HME)
Study: 17473095
Drug: High maternal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High maternal antibody levels in serum and breast milk
Study: 15061863
Drug: Patient Information
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient Information Leaflet (PIL) on oral cancer
Study: 9665188
Drug: Four cycles
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four cycles of intensive chemotherapy (short arm)
Study: 9665188
Drug: Eight cycles
Normalized name: OC Eight
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eight cycles of intensive chemotherapy (long arm)
Study: 10150267
Drug: Pefloxacin 400
Normalized name: pefloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pefloxacin 400 mg in 100‐mL solution as an intravenous infusion (1 dose)
Study: 10150267
Drug: Pefloxacin 400
Normalized name: pefloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pefloxacin 400 mg in 100‐mL solution as an intravenous infusion (2 doses)
Study: 10150267
Drug: Pefloxacin 400
Normalized name: pefloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pefloxacin 400 mg in 100‐mL solution as an intravenous infusion (6 doses)
Study: 1064904
Drug: Rapidly-disintegrating tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapidly-disintegrating tablets with a standardized breakfast meal
Study: 1064904
Drug: Slow-release tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release tablets with a standardized breakfast meal
Study: 1064904
Drug: Rapidly-disintegrating tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapidly-disintegrating tablets under fasting conditions
Study: 1064904
Drug: Slow-release tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release tablets under fasting conditions
Study: 17915181
Drug: Computer-assisted cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-assisted cognitive training (20 sessions, 30-45 minutes each, twice a week)
Study: 11563466
Drug: Vaginal dinoprostone
Normalized name: dinoprostone Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal dinoprostone (2mg, two doses administered six hours apart)
Study: 2686422
Drug: Intravenous ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ciprofloxacin 200 mg twice daily
Study: 2686422
Drug: Ceftazidime 1
Normalized name: ceftazidime 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 1 to 2 g every eight to 12 hours
Study: 31053081
Drug: LOV group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOV group (low VT of 3-4 ml/kg IBW, RR of 10-12 acts/min, PEEP of 5-8 cmH2O, FiO2 30%)
Study: 31053081
Drug: HOV group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: HOV group (low VT of 3-4 ml/kg IBW, RR of 10-12 acts/min, PEEP of 5-8 cmH2O, FiO2 80%)
Study: 25872610
Drug: Losartan treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan treatment for 6 months
Study: 25872610
Drug: Irbesartan treatment
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Irbesartan treatment (in independent trials IDNT and IRMA-2)
Study: 21488723
Drug: Desensitizing agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desensitizing agent (5% potassium nitrate/2% sodium fluoride)
Study: 19660004
Drug: Omalizumab (anti-IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab (anti-IgE antibody), subcutaneously administered, dosage not specified, duration of treatment not specified.
Study: 15244210
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg b.d., amoxycillin 1000 mg b.d., clarithromycin 500 mg b.d.
Study: 15244210
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg b.d., amoxycillin 1000 mg b.d., clarithromycin 500 mg b.d.
Study: 2794839
Drug: Caffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated coffee (100 mg/cup)
Study: 2794839
Drug: Caffeine capsules
Normalized name: Butalbital, Aspirin, and Caffeine Capsules
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine capsules (100 mg/capsule)
Study: 690226
Drug: Marijuana high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marijuana high dose
Study: 690226
Drug: Marijuana low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marijuana low dose
Study: 690226
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose marijuana in odor session
Study: 690226
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose marijuana in odor session
Study: 23177515
Drug: Regorafenib 160
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib 160 mg daily
Study: 21295286
Drug: Varenicline 1
Normalized name: varenicline 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline 1 mg twice daily (n = 55)
Study: 19369829
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (omeprazole 20 mg once daily, clarithromycin 250 mg twice daily, tinidazole 500 mg twice daily)
Study: 19369829
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (among H. pylori eradicated patients)
Study: 16688094
Drug: ARV +
Normalized name: Arv-110 (protac)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARV + HU (Hydroxyurea 500 mg BID)
Study: 9255270
Drug: Alternating treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating treatments of CAV and PE
Study: 31200280
Drug: Conservative medical
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative medical therapy
Study: 27133564
Drug: YAB group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: YAB group (200 g of yoghurt supplemented with Bifidobacterium longum during both diet periods)
Study: 20216071
Drug: Group L
Normalized name: Blood group Lewis alpha-4-fucosyltransferase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group L (luteal phase)
Study: 18624972
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (TU) 1,000 mg alone
Study: 18624972
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (TU) + Dutasteride (D) 0.5 mg/die
Study: 18624972
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (TU) + Letrozole (L) 2.5 mg/die
Study: 16440580
Drug: Calcipotriol solution
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol solution 50 g/ml, applied twice daily for 8 weeks
Study: 10569667
Drug: Theophylline (adenosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (adenosine receptor antagonist)
Study: 6364399
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg tendamistate with 100 g maize meal
Study: 6364399
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg tendamistate with 100 g maize meal
Study: 6364399
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg tendamistate with 100 g maize meal
Study: 6364399
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with 100 g maize meal
Study: 27506971
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BtX‐A) injection (200 IU) in the quadriceps muscles
Study: 14742982
Drug: Iron supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplements with morning dose of MMF (n=14)
Study: 14742982
Drug: Iron supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplements given 4 hr after MMF at midday (n=13)
Study: 14742982
Drug: No iron
Normalized name: No Iron Multivitamin with Minerals
Approvals — FDA: no, EMA: no, PMDA: no
Description: No iron supplements (n=13)
Study: 11577951
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group in surgical treatment
Study: 11577951
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group in non-surgical treatment
Study: 9628449
Drug: Enoxaparin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (30 mg IV bolus followed by SC injections of 1.0 mg/kg every 12 hours)